Brittany Clark, MD
Internal Medicine · Monroe, LANPI 1821383431
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 165 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $708 and has fallen 94.1% since, to $41 in 2025.
Across 165 payments — averaging $17.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$580
- AbbVie$257
- Abbott$206
- Astellas Pharma US Inc$188
- Amgen$176
- AstraZeneca$163
- plus $1K from 16 others
What the payments were for
- Food & beverage$2,851100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 35 | $580 |
| AbbVie(2 entities) | 15 | $257 |
| Abbott | 3 | $206 |
| Astellas Pharma US Inc | 12 | $188 |
| Amgen | 11 | $176 |
| AstraZeneca | 11 | $163 |
| Lilly USA, LLC | 10 | $162 |
| Pfizer | 9 | $154 |
| Johnson & Johnson | 10 | $146 |
| Bayer | 7 | $142 |
| GSK | 7 | $113 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $108 |
| Boehringer Ingelheim | 5 | $105 |
| Sanofi-aventis U.S. LLC | 7 | $102 |
| Amarin Pharma, Inc. | 5 | $83 |
| Merck | 4 | $55 |
| Almatica Pharma LLC | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Boston Scientific | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,851 in reported general payments places this provider in the 80th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 112 | $122,396 |
| EliquisApixaban | 66 | $96,133 |
| JanuviaSitagliptin Phosphate | 92 | $89,056 |
| FarxigaDapagliflozin Propanediol | 63 | $74,810 |
| OzempicSemaglutide | 49 | $67,850 |
| TrulicityDulaglutide | 28 | $48,979 |
| LinzessLinaclotide | 35 | $24,934 |
| MounjaroTirzepatide | 15 | $24,629 |
| RybelsusSemaglutide | 16 | $23,174 |
| KerendiaFinerenone | 21 | $20,645 |
| MyrbetriqMirabegron | 28 | $18,145 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $12,889 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $11,980 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 13 | $11,236 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $10,775 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $105 | $122,396112 claims |
| MerckJanuvia, Janumet, Janumet Xr | $55 | $113,181117 claims |
| PfizerEliquis | $154 | $96,13366 claims |
| Novo NordiskOzempic, Rybelsus | $580 | $91,02465 claims |
| AstraZenecaFarxiga, Symbicort | $163 | $85,58682 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $162 | $73,60843 claims |
| AbbVieLinzess | $257 | $24,93435 claims |
| BayerKerendia | $142 | $20,64521 claims |
| Astellas Pharma US IncMyrbetriq | $188 | $18,14528 claims |
| GSKTrelegy Ellipta | $113 | $11,98013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Monroe
- Donna RyanBaton Rouge$991K
- Steven DeitelzweigNew Orleans$939K
- Bruce SamuelsCovington$200K
- Amanda FontenotMarrero$142K
- John SchwabBaton Rouge$122K
- Daniel EnglertNew Orleans$74K
- Everett BrownGretna$71K
- Rajan KhannaShreveport$54K
- Samuel StaggEunice$54K
- Bryan LebeanLafayette$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.